Loading organizations...
Genz Biotech is a biotechnology startup based in London, United Kingdom, that develops in vitro diagnostic tests, point-of-care solutions, and personalized therapeutics for early disease detection and management. Operating with a workforce of 50 employees, the company focuses on creating accessible diagnostic tools targeting major public health challenges, including breast cancer and COVID-19, specifically for low-income and rural communities. The enterprise utilizes a business-to-business commercialization model to distribute its medical products to hospitals, clinics, universities, and healthcare professionals through established vendor chains and international distributors. To date, Genz Biotech has commercialized four legalized IVD diagnostic tests and three CE-IVD genetic tests while establishing collaborative research partnerships with Harvard, Brown University, and ETH Zurich. The organization was founded in 2017 by chief executive officer Umut Ağyüz as a spin-off from Middle East Technical University.
Genz Biotech has raised $100K across 1 funding round.
Genz Biotech has raised $100K in total across 1 funding round.
Genz Biotech has raised $100K across 1 funding round. Most recently, it raised $100K Seed in July 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2020 | $100K Seed | — | Vela Partners | Announced |
Genz Biotech has raised $100K in total across 1 funding round.
Genz Biotech's investors include Vela Partners.
Genz Biotechnology is a biotech startup developing innovative in vitro diagnostic (IVD) solutions, including molecular and genetic tests, PCR kits, ELISA kits, and a point-of-care testing (POCT) platform called GENZPRO for early diagnosis and personalized therapy.[1][2][3] Headquartered in London with operations in Turkey, founded in 2017, it serves healthcare professionals, labs, clinics, pharmacies, and patients by addressing challenges like breast cancer screening, fetal RH testing, liquid biopsy gender tests, and COVID-19 detection through affordable, rapid, portable devices with SaaS cloud support.[1][2][3][6] The company has secured research grants, achieved CE-IVD certification, commercialized its platform in 2022, and plans wellness testing for end-users, demonstrating steady growth with 11-50 employees and reported revenue around $13.5 million.[1][2][3][7]
Genz Biotechnology emerged as a university spin-off from a prestigious institution, founded in 2017 by Umut Ağyüz (CEO, Biomedical PhD with R&D and commercialization experience) and Caner Demir (CEO, focused on accessible healthcare solutions), with Dia Akilli as Chief Sales Officer bringing business leadership expertise.[1][2][3][4] The idea stemmed from targeting global health challenges, initially spurred by the need for rapid SARS-CoV-2 testing with the GENZPRO platform and antibody tests, evolving from diagnostics to therapeutics for complex diseases like breast cancer and COVID-19.[1][2][6][7] Early traction included research grants, CE-IVD approvals for tests, and commercialization of the GENZPRO device in early 2022, backed by investors like Erdem Gülen.[1][3]
Genz rides the wave of point-of-care diagnostics and personalized medicine, fueled by post-COVID demand for fast, decentralized testing amid rising chronic diseases like cancer and global health inequities.[1][2][6] Timing aligns with POCT market growth, where portable tech bridges lab access gaps in underserved areas, supported by regulatory nods like CE-IVD and grants enabling scalability.[1][3] Market forces favoring Genz include biotech R&D funding, SaaS integration for data-driven care, and partnerships expanding distribution; it influences the ecosystem by pioneering mass testing and therapeutics spin-offs, potentially democratizing healthcare in emerging markets.[1][2][7]
Genz is poised for US FDA pursuits and global distribution growth, targeting leadership in POCT with GENZPRO devices and wellness tests to enhance early detection worldwide.[1][3] Trends like AI-enhanced diagnostics, telehealth integration, and personalized genomics will amplify its trajectory, evolving its influence from niche innovator to mass-market enabler in accessible biotech. This positions Genz to sustain momentum from its grant-funded origins, delivering value in an era of urgent health innovation.[1][2]
